Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.
| Revenue (Most Recent Fiscal Year) | $47.98M |
| Net Income (Most Recent Fiscal Year) | $-68.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.17 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.84 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -107.39% |
| Net Margin (Trailing 12 Months) | -108.11% |
| Return on Equity (Trailing 12 Months) | -125.91% |
| Return on Assets (Trailing 12 Months) | -57.58% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.83 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.83 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.85 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 56.34M |
| Free Float | 53.24M |
| Market Capitalization | $128.45M |
| Average Volume (Last 20 Days) | 0.44M |
| Beta (Past 60 Months) | 1.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 25.60% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |